葛兰素史克Glaxosmithkline（GSK）2025年第三季度投资者和分析师财报电话会议PPT「LSE」（英文版）（40页）.pdf

1、Q3 2025 ResultsQ3 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts29 October 202529 October 20252AgendaAgendaQ3 2025 strong performance improves furtherQ3 2025 strong performance improves furtherEmma WalmsleyPerformance:growth d

2、riversPerformance:growth driversLuke Miels and Deborah WaterhouseQ3 2025 financial performanceQ3 2025 financial performanceJulie BrownSummary and Q&ASummary and Q&AEmma Walmsley,Luke Miels,Deborah Waterhouse,Julie Brown,Tony Wood and David RedfernThis presentation may contain forward-looking stateme

3、nts.Forward-looking statements give the Groups current expectations or forecasts of future events.An investor can identify these statements by the fact that they do not relate strictly to historical or current facts.They use words such as anticipate,estimate,expect,intend,will,project,plan,believe,t

4、arget and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.In particular,these include statements relating to future actions,prospective products or product approvals,future performance or results of current and anticipated produ

5、cts,sales efforts,expenses,the outcome of contingencies such as legal proceedings,dividend payments and financial results.Other than in accordance with its legal or regulatory obligations(including under the Market Abuse Regulations,UK Listing Rules and the Disclosure Guidance and Transparency Rules

6、 of the Financial Conduct Authority),the Group undertakes no obligation to update any forward-looking statements,whether as a result of new information,future events or otherwise.Investors should,however,consult any additional disclosures that the Group may make in any documents which it publishes a